Sentien Biotechnologies, Inc.   Report issue

For profit Phase 2
Founded: Lexington MA United States (2008)

Organization Overview

First Clinical Trial
2017
NCT03015623
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Sentien Biotechnologies, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

sbi-101 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1